Patents by Inventor Mauro Marzi
Mauro Marzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181475Abstract: The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.Type: ApplicationFiled: May 10, 2021Publication date: June 15, 2023Applicant: ALFASIGMA S.P.A.Inventors: Mauro Marzi, Mose' Santaniello, Pietro Meloni, Marta Paris, Fabrizio Giorgi, Emilio Merlo Pich
-
Patent number: 8598384Abstract: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.Type: GrantFiled: July 31, 2008Date of Patent: December 3, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Emanuela Tassoni
-
Patent number: 8269007Abstract: This invention relates to a process for preparing a crystalline form of (4S)-11(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3?4?:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing from methanol.Type: GrantFiled: July 22, 2008Date of Patent: September 18, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpAInventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Elena Badaloni, Silvia Armaroli, Giuseppe Marazzi
-
Patent number: 8124769Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: GrantFiled: August 17, 2010Date of Patent: February 28, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Patent number: 8101758Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: GrantFiled: August 17, 2010Date of Patent: January 24, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Patent number: 8053460Abstract: Indole derivatives of Formula (I+A) having antitumor and chemosensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumors.Type: GrantFiled: May 31, 2006Date of Patent: November 8, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Gianfranco Battistuzzi, Maria Di Marzo, Giuseppe Giannini, Mauro Marzi, Loredana Vesci, Franco Zunino
-
Publication number: 20110136905Abstract: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.Type: ApplicationFiled: July 31, 2008Publication date: June 9, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Emanuela Tassoni
-
Patent number: 7851621Abstract: A process for the synthesis of deoxybiotinyl hexamethylenediamine0-DOTA is herein described. Said process comprises reacting biotinyl hexamithylenediamine with tri-t-butyl DOTA in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, as the condensing agent, and triethylamine, as a base.Type: GrantFiled: May 31, 2006Date of Patent: December 14, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Mauro Marzi, Maria Di Marzo
-
Publication number: 20100311784Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPAInventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Publication number: 20100311783Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPAInventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Patent number: 7816386Abstract: Cinnamic and phenylpropiolic acid derivatives of formula (I) having antitumour and chemo sensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.Type: GrantFiled: May 31, 2006Date of Patent: October 19, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Gianfranco Battistuzzi, Maria Di Marzo, Giuseppe Giannini, Mauro Marzi, Loredana Vesci, Franco Zunino, Riccardo Pezzi
-
Publication number: 20100249414Abstract: This invention relates to a process for preparing a crystalline form of (4S)-11-(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3?,4?:6,7]indolizino[1,2-b]qui-noline-3,14(4H,12H)-dione (also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing it from methanol.Type: ApplicationFiled: July 22, 2008Publication date: September 30, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Elena Badaloni, Silvia Armaroli, Giuseppe Marazzi
-
Patent number: 7799921Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: GrantFiled: December 16, 2005Date of Patent: September 21, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Publication number: 20100184972Abstract: A process for the synthesis of deoxybiotinyl hexamethylenediamine0-DOTA is herein described. Said process comprises reacting biotinyl hexamithylenediamine with tri-t-butyl DOTA in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, as the condensing agent, and triethylamine, as a base.Type: ApplicationFiled: May 31, 2006Publication date: July 22, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Mauro Marzi, Maria Di Marzo
-
Publication number: 20090239893Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: ApplicationFiled: December 16, 2005Publication date: September 24, 2009Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Patent number: 7572778Abstract: The present invention is related to new derivatives of Combretastatin, of Formula obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation—as anticancer and/or antiangiogenic activity, in a mammal—to pharmaceutical compositions comprising these compounds.Type: GrantFiled: July 6, 2004Date of Patent: August 11, 2009Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Giuseppe Giannini, Domenico Alloatti, Marcella Marcellini, Mauro Marzi, Teresa Riccioni, Maria Ornella Tinti
-
Patent number: 7498340Abstract: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.Type: GrantFiled: April 10, 2007Date of Patent: March 3, 2009Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituto Nazionale per Lo Studio E La Cura Dei TumoriInventors: Mauro Marzi, Domenico Alloatti, Claudio Pisano, Maria Ornella Tinti, Loredana Vesci, Franco Zunino
-
Patent number: 7452900Abstract: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.Type: GrantFiled: May 28, 2003Date of Patent: November 18, 2008Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituto Nazionale Per lo Studio e la Cura Dei TumoriInventors: Mauro Marzi, Domenico Alloatti, Caludio Pisano, Maria Ornella Tinti, Vesci Loredana, Zunino Franco
-
Patent number: RE40861Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.Type: GrantFiled: November 30, 2006Date of Patent: July 21, 2009Assignee: Sigma-Tau Industrie Farmaceutiche Reunite S.p.A.Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria O. Tinti, Piero Chiodi, Arduino Arduini
-
Patent number: RE41226Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine polymitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.Type: GrantFiled: December 1, 2006Date of Patent: April 13, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria Ornella Tinti, Piero Chiodi, Arduino Arduini